Pharmacodynamics of ceftolozane combined with tazobactam against Enterobacteriaceae in a neutropenic mouse thigh model

Antimicrobial Agents and Chemotherapy

Volumn 60, Issue 12, 2016, Pages 7272-7279

  Melchers, M J ^a   Mavridou, E ^a,d   Van Mil, A C ^a,b   Lagarde, C ^a   Mouton, J W ^a,c  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

^c ERASMUS MEDICAL CENTER   (Netherlands)

^d WEILL CORNELL MEDICAL COLLEGE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CEFTOLOZANE; TAZOBACTAM; ANTIINFECTIVE AGENT; BETA LACTAMASE; BETA-LACTAMASE CTX-M, E COLI; CEPHALOSPORIN DERIVATIVE; ESCHERICHIA COLI PROTEIN; PENICILLANIC ACID;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIBACTERIAL ACTIVITY; ARTICLE; BACTERIUM ISOLATE; CONTROLLED STUDY; DOSE RESPONSE; DRUG ELIMINATION; DRUG PROTEIN BINDING; ENTEROBACTERIACEAE; ESCHERICHIA COLI; KLEBSIELLA PNEUMONIAE; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NEUTROPENIA; NONHUMAN; PHARMACODYNAMICS; PRIORITY JOURNAL; THIGH; ANALOGS AND DERIVATIVES; ANIMAL; COMBINATION DRUG THERAPY; DRUG EFFECTS; FEMALE; GENETICS; GROWTH, DEVELOPMENT AND AGING; MICROBIAL SENSITIVITY TEST;

ANIMALS; ANTI-BACTERIAL AGENTS; BETA-LACTAMASES; CEPHALOSPORINS; DRUG THERAPY, COMBINATION; ESCHERICHIA COLI; ESCHERICHIA COLI PROTEINS; FEMALE; KLEBSIELLA PNEUMONIAE; MICE; MICROBIAL SENSITIVITY TESTS; PENICILLANIC ACID;

EID: 84996567043     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.01580-16     Document Type: Article

References (21)

1. Bradford PA. 2001. Extended-spectrum beta-lactamases in the 21st century: characterization, epidemiology, and detection of this important resistance threat. Clin Microbiol Rev 14:933-951. http://dx.doi.org/10.1128/CMR.14.4.933-951.2001.
2. Bush K. 2013. Proliferation and significance of clinically relevant beta-lactamases. Ann N Y Acad Sci 1277:84-90. http://dx.doi.org/10.1111/nyas.12023.
3. Lukac PJ, Bonomo RA, Logan LK. 2015. Extended-spectrum beta-lactamase-producing Enterobacteriaceae in children: old foe, emerging threat. Clin Infect Dis 60:1389-1397. http://dx.doi.org/10.1093/cid/civ020.
4. Giamarellou H. 2008. Beta-lactams without a suicide inhibitor. Clin Microbiol Infect 14(Suppl 1):S194-S197.
5. Livermore DM, Mushtaq S, Ge Y. 2010. Chequerboard titration of cephalosporin CXA-101 (FR264205) and tazobactam versus beta-lactamase-producing Enterobacteriaceae. J Antimicrob Chemother 65:1972-1974. http://dx.doi.org/10.1093/jac/dkq248.
6. Melchers MJ, van Mil AC, Mouton JW. 2015. In vitro activity of ceftolozane alone and in combination with tazobactam against extended-spectrum-beta-lactamase-harboring Enterobacteriaceae. Antimicrob Agents Chemother 59:4521-4525. http://dx.doi.org/10.1128/AAC.04498-14.
7. Bulik CC, Tessier PR, Keel RA, Sutherland CA, Nicolau DP. 2012. In vivo comparison of CXA-101 (FR264205) with and without tazobactam versus piperacillin-tazobactam using human simulated exposures against phenotypically diverse gram-negative organisms. Antimicrob Agents Chemother 56:544-549. http://dx.doi.org/10.1128/AAC.01752-10.
8. Mavridou E, Melchers RJ, van Mil AC, Mangin E, Motyl MR, Mouton JW. 2015. Pharmacodynamics of imipenem in combination with beta-lactamase inhibitor MK7655 in a murine thigh model. Antimicrob Agents Chemother 59:790-795. http://dx.doi.org/10.1128/AAC.03706-14.
9. Berkhout J, Melchers MJ, van Mil AC, Seyedmousavi S, Lagarde CM, Schuck VJ, Nichols WW, Mouton JW. 2016. Pharmacodynamics of ceftazidime and avibactam in neutropenic mice with thigh or lung infection. Antimicrob Agents Chemother 60:368-375. http://dx.doi.org/10.1128/AAC.01269-15.
10. VanScoy B, Mendes RE, Nicasio AM, Castanheira M, Bulik CC, Okusanya OO, Bhavnani SM, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacokinetics-pharmacodynamics of tazobactam in combination with ceftolozane in an in vitro infection model. Antimicrob Agents Chemother 57:2809-2814. http://dx.doi.org/10.1128/AAC.02513-12.
11. Buijs J, Dofferhoff AS, Mouton JW, van der Meer JW. 2007. Continuous administration of PBP-2- and PBP-3-specific beta-lactams causes higher cytokine responses in murine Pseudomonas aeruginosa and Escherichia coli sepsis. J Antimicrob Chemother 59:926-933. http://dx.doi.org/10.1093/jac/dkm073.
12. Mouton JW, van Ogtrop ML, Andes D, Craig WA. 1999. Use of pharmacodynamic indices to predict efficacy of combination therapy in vivo. Antimicrob Agents Chemother 43:2473-2478.
13. Zuluaga AF, Salazar BE, Rodriguez CA, Zapata AX, Agudelo M, Vesga O. 2006. Neutropenia induced in outbred mice by a simplified low-dose cyclophosphamide regimen: characterization and applicability to diverse experimental models of infectious diseases. BMC Infect Dis 6:55. http://dx.doi.org/10.1186/1471-2334-6-55.
14. Melchers MJ, Mavridou E, Seyedmousavi S, van Mil AC, Lagarde C, Mouton JW. 2015. Plasma and epithelial lining fluid pharmacokinetics of ceftolozane and tazobactam alone and in combination in mice. Antimicrob Agents Chemother 59:3373-3376. http://dx.doi.org/10.1128/AAC.04402-14.
15. International Organization for Standardization. 2006. ISO 20776-1: 2006. Clinical laboratory testing and in vitro diagnostic test systems - susceptibility testing of infectious agents and evaluation of performance of antimicrobial susceptibility test devices. Part 1. Reference method for testing the in vitro activity of antimicrobial agents against rapidly growing aerobic bacteria involved in infectious diseases. International Organization for Standardization, Geneva, Switzerland.
16. VanScoy B, Mendes RE, McCauley J, Bhavnani SM, Bulik CC, Okusanya OO, Forrest A, Jones RN, Friedrich LV, Steenbergen JN, Ambrose PG. 2013. Pharmacological basis of beta-lactamase inhibitor therapeutics: tazobactam in combination with ceftolozane. Antimicrob Agents Chemother 57:5924-5930. http://dx.doi.org/10.1128/AAC.00656-13.
17. Craig WA, Andes DR. 2013. In vivo activities of ceftolozane, a new cephalosporin, with and without tazobactam against Pseudomonas aeruginosa and Enterobacteriaceae, including strains with extended-spectrum beta-lactamases, in the thighs of neutropenic mice. Antimicrob Agents Chemother 57:1577-1582. http://dx.doi.org/10.1128/AAC.01590-12.
18. Mouton J, Mavridou M, Donnelly R, Van Mil A. 2011. PK/PD of betalactam-betalactamase inhibitors: correlation of in vitro susceptibility testing with in vivo efficacy, poster A-1687. Abstr 51st Intersci Conf Antimicrob Agents Chemother, Chicago, IL. American Society for Microbiology, Washington, DC.
19. Paltansing S, Kraakman M, van Boxtel R, Kors I, Wessels E, Goessens W, Tommassen J, Bernards A. 2015. Increased expression levels of chromosomal AmpC beta-lactamase in clinical Escherichia coli isolates and their effect on susceptibility to extended-spectrum cephalosporins. Microb Drug Resist 21:7-16. http://dx.doi.org/10.1089/mdr.2014.0108.
20. Goldsmith M, Tawfik DS. 2009. Potential role of phenotypic mutations in the evolution of protein expression and stability. Proc Natl Acad Sci U S A 106:6197-6202. http://dx.doi.org/10.1073/pnas.0809506106.
21. Muller A, Baghwat S, Patel M, Mouton J. 2016. Development of a population pharmacokinetic model of tazobactam including high doses, poster 500. Abstr 56th Intersci Conf Antimicrob Agents Chemother, Boston, MA. American Society for Microbiology, Washington, DC.